Eric Schaefer

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Comparison of standard two-dimensional and three-dimensional corrected glenoid version measurements

Matthew D. Budge, Gregory S. Lewis, Eric Schaefer et al. · Journal of Shoulder and Elbow Surgery · 2011 · 199 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +11

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 93 citations · Full text

Medicine, Oncology, Pharmacology +13

Attributable costs of differentiated thyroid cancer in the elderly Medicare population

Melissa Boltz, Christopher S. Hollenbeak, Eric Schaefer et al. · Surgery · 2013 · 46 citations

Medicine, Geriatric Medicine, Oncology +15